Nebivololo Doc (Nebivolol Hydrochloride)

Nebivolol selectively antagonizes β1‑adrenergic receptors in the heart, decreasing heart rate and contractility, which lowers blood pressure. Simultaneously, it stimulates endothelial nitric‑oxide synthase, increasing nitric oxide release that causes peripheral vasodilation. The dual action of β1 blockade and nitric‑oxide‑mediated vessel relaxation results in reduced systemic vascular resistance and improved cardiac efficiency.

The dosage of nebivolol is individualized by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and response to therapy. Typical starting doses may be low and adjusted upward as needed, but exact strength and regimen must be determined by a qualified prescriber and reflected on the prescription label.

The safety of nebivolol during pregnancy and lactation has not been definitively established, and it is generally classified as contraindicated or used only when the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Nebivololo Doc product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Compared with older non‑selective beta‑blockers, nebivolol offers β1‑selectivity and an additional nitric‑oxide‑mediated vasodilatory effect, which may result in fewer metabolic side effects and better tolerability in some patients. However, clinical choice depends on individual patient characteristics, comorbidities, and physician experience, and other agents such as metoprolol or bisoprolol remain appropriate alternatives in many treatment protocols.

Nebivololo Doc tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date printed on the label. No refrigeration is required for this oral formulation.

Nebivololo Doc is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed. Patients should follow the dosing schedule on the prescription label and report any missed doses to their healthcare provider.

The most serious adverse reactions to nebivolol include severe bradycardia, symptomatic hypotension, and bronchospasm, particularly in patients with pre‑existing respiratory disorders. Rare but critical events such as heart block, acute heart failure exacerbation, or severe allergic reactions may also occur. Prompt medical attention is required if any of these symptoms develop while using the medication.

Nebivolol is contraindicated in patients with known hypersensitivity to nebivolol or any component of the formulation, in those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and in individuals with uncompensated heart failure or cardiogenic shock. Caution is also advised for patients with severe asthma, chronic obstructive pulmonary disease, or significant hepatic impairment. Such patients should discuss alternative therapies with their physician.